|
Re: Rebuys start at $2.28
|
5
|
Resverlogix Corp.
|
Aug 09, 2018 05:46PM
|
|
Re: Rebuys start at $2.28
|
4
|
Resverlogix Corp.
|
Aug 09, 2018 11:29PM
|
|
Re: Reata, Friedreich’s Ataxia and Kidney Disease
|
8
|
Resverlogix Corp.
|
Oct 17, 2019 09:50PM
|
|
Re: Reata, Friedreich’s Ataxia and Kidney Disease
|
4
|
Resverlogix Corp.
|
Oct 17, 2019 10:55PM
|
|
Re: Reata, Friedreich’s Ataxia and Kidney Disease
|
3
|
Resverlogix Corp.
|
Oct 18, 2019 06:58AM
|
|
Re: Reata, Bardoxolone, NRF2, CKD, Mitochondria, Inflammation, Redox Balance, Reactive Oxygen Species
|
2
|
Resverlogix Corp.
|
Jun 14, 2019 10:04PM
|
|
Re: Reata, Bardoxolone, NRF2, CKD, Mitochondria, Inflammation, Redox Balance, Reactive Oxygen Species
|
2
|
Resverlogix Corp.
|
Jun 14, 2019 09:34AM
|
|
Re: Reata, Bardoxolone, NRF2, CKD, Mitochondria, Inflammation, Redox Balance, Reactive Oxygen Species
|
1
|
Resverlogix Corp.
|
Jun 14, 2019 11:48AM
|
|
Re: Reata, Bardoxolone, NRF2, CKD, Mitochondria, Inflammation, Redox Balance, Reactive Oxygen Species
|
4
|
Resverlogix Corp.
|
Jun 14, 2019 01:38PM
|
|
Re: Reata, Bardoxolone, NRF2, CKD, Mitochondria, Inflammation, Redox Balance, Reactive Oxygen Species
|
2
|
Resverlogix Corp.
|
Jun 14, 2019 03:00PM
|
|
Re: Reata, Bardoxolone, NRF2, CKD, Mitochondria, Inflammation, Redox Balance, Reactive Oxygen Species
|
1
|
Resverlogix Corp.
|
Jun 14, 2019 03:42PM
|
|
Re: Reading The Tea Leaves
|
2
|
Resverlogix Corp.
|
May 31, 2017 12:29PM
|
|
Re: Reaching 250 MACE
|
5
|
Resverlogix Corp.
|
Apr 23, 2019 11:09AM
|
|
Re: Re-visiting Tundup's all-time top-rated message
|
2
|
Resverlogix Corp.
|
Jan 22, 2019 12:12PM
|
|
Re: Re-visiting Tundup's all-time top-rated message
|
1
|
Resverlogix Corp.
|
Jan 22, 2019 12:26PM
|
|
Re: Re San fran
|
10
|
Resverlogix Corp.
|
Oct 19, 2020 11:30AM
|
|
Re: RBC unregistered to registered account
|
3
|
Zenith Epigenetics
|
Apr 01, 2019 08:11PM
|
|
Re: RBC unregistered to registered account
|
5
|
Zenith Epigenetics
|
Apr 01, 2019 09:25PM
|
|
Re: Rationale and Design of Apabetalone BETonMACE Trial
|
5
|
Resverlogix Corp.
|
Dec 03, 2018 03:42PM
|
|
Re: Rationale and Design of Apabetalone BETonMACE Trial
|
3
|
Resverlogix Corp.
|
Dec 03, 2018 04:03PM
|
